Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

a technology of fluticasone and nanocrystals, which is applied in the field of preparation of sterile topical ophthalmic nanosuspensions, can solve the problems of loss of stabilizing effect, difficult de-agglomeration of nanocrystals, and difficult storage, so as to improve the preservation of multi-dose ophthalmic compositions, stable nanosuspensions, and easy adaptability to large-scale preparations

Pending Publication Date: 2022-08-04
NICOX OPHTHALMICS
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The text discusses the use of complexes of boric acid with polyhydroxyl compounds (known as borate-polyol complexes) in ophthalmic compositions to enhance antimicrobial activity. The patent describes a method of improving the preservation of multi-dose ophthalmic compositions by using Borate-polyol complexes containing two different polyols. The technical effect of this is the improved antimicrobial activity of ophthalmic compositions, which helps to prevent microbial contamination and ensure their safety and effectiveness.

Problems solved by technology

When the nanocrystals of Fluticasone propionate are directly suspended and de-agglomerated in a final vehicle that contains the pre-formed boric acid / glycerol complex the stabilizing effect is lost and the de-agglomeration of the nanocrystals is more difficult to achieve and to maintain during the storage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
  • Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
  • Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0124]Preparation of Nanocrystals of Fluticasone Propionate Form A

[0125]Preparation of Phase I Solution

[0126]In a 2 L process vessel, 106.26 g polysorbate 80 (Tween 80), 963.34 g polypropylene glycol 400 (PPG 400), 324.10 g polyethylene glycol 400 (PEG 400), were added at room temperature and stirred together until all components were dissolved, then 6.3 g fluticasone propionate polymorph 1 was added into the solution and stirred until a clear solution was obtained. The obtained solution was filtered using a 0.8 / 0.2 μm Polyethersulfone (PES) filter and kept refrigerated at 2-8° C. until use.

[0127]Preparation of Phase II Solution

[0128]In an 8 L process vessel an initial quantity of about 5276 g of purified water was added and stirred with an over-head mixer so that a vortex was generated.

[0129]6.01 g polyethylene glycol 40 stearate (PEG-40 stearate), 5.98 g benzalkonium chloride (solution 10%), and 24.02 g methyl cellulose 15 cP were added and stirred till methyl cellulose was comple...

example 2

[0147]Preparation of a Sterile Topical Ophthalmic Aqueous Nanosuspension of Fluticasone Propionate Form A

TABLE 1Fluticasone propionate nanosuspension compositionIngredientsAmount (% w / w)Fluticasone propionate Form A nanocrystals0.10Methylcellulose 4000 cP0.50Polysorbate 800.2Edetate disodium, dihydrate0.10Boric acid1.0Glycerin0.9Benzalkonium chloride0.01Sodium chloride0.055Water for injectionq.s. to 100%pH7.3-7.5

[0148]Step 1) Preparation of Vehicle 1 (Vehicle without Glycerin)

[0149]In a 20 L process vessel, 17600 g water for injection were heated at 80° C., 100.0 g methylcellulose 4000 cP were slowly added and the mixture is stirred until methylcellulose was dissolved.

[0150]The solution was cooled at 40° C., 200.0 g boric acid was added and the pH was adjusted at 7.4 with sodium hydroxide (1N).

[0151]The following excipients were added in the specific following order: 20.0 g edetate disodium dihydrate, 11.0 g sodium chloride, 4.0 g benzalkonium chloride (solution 50%), 40.0 g polysor...

example 3

[0188]Evaluation of the Stability of the Nanosuspension of Example 2

[0189]The nanosuspension composition prepared in example 2 was subjected to storage stability testing by storing the nanosuspension at three different temperatures and humidity conditions (5° C., 25° C. / 40% RH; 40° C. / 25% RH) The resuspendability of the nanosuspension, the content of fluticasone propionate, the particle size distribution and the content of benzalkonium chloride were assessed at 1 month and 3-month time-points.

[0190]The results reported in tables 2 and 3 show that the nanosuspension was physically and chemically stable upon manufacture and storage. No change in physical appearance of the nanosuspension upon storage was noticed. The nanosuspension did not show any sign of chemical degradation as the chemical assay of fluticasone propionate was well within the limit of 90%-110% of the label claim upon storage. The related substances and total impurities remained within the specified limits of not more ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
mean particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a process for the preparation of sterile topical ophthalmic nanosuspensions containing nanocrystals of fluticasone propionate Form A in an aqueous vehicle. This process is readily adaptable to preparation for large-scale production and leads to sterile homogeneous aqueous nanosuspensions having a stable particle size distribution.[0002]The sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals are useful in the treatment of eye inflammation diseases or eye inflammatory conditions through topical administration of said nanosuspensions (or nanocrystals suspensions) to eyelids (e.g. upper and lower lids), eyelashes and eyelid margin.BACKGROUND OF THE INVENTION[0003]Nanocrystals of fluticasone propionate Form A are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates. The fluticasone propionate Form A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/569A61K9/10A61K9/00A61K47/38A61K47/26A61K47/18A61K47/02A61K47/10A61P27/04
CPCA61K31/569A61K9/10A61K9/0048A61K47/38A61P27/04A61K47/183A61K47/02A61K47/10A61K47/186A61K47/26A61K31/56A61P27/02A61P29/00B82Y5/00C07J31/006A61P27/00A61K9/14C07B2200/13A61K9/08A61K31/567
Inventor BUKOWSKI, JEAN-MICHELNADKARNI, AKSHAYBOYER, JOSÉ L.DUQUESROIX-CHAKROUN, BRIGITTENAVRATIL, TOMAS
Owner NICOX OPHTHALMICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com